Below are the most recent publications written about "Sildenafil Citrate" by people in Profiles.
-
Jackson W, Gonzalez D, Smith PB, Ambalavanan N, Atz AM, Sokol GM, Hornik CD, Stewart D, Mundakel G, Poindexter BB, Ahlfeld SK, Mills M, Cohen-Wolkowiez M, Martz K, Hornik CP, Laughon MM. Safety of sildenafil in extremely premature infants: a phase I trial. J Perinatol. 2022 01; 42(1):31-36.
-
El Hajj MC, Cai AW, Houston BA, Tedford RJ. Recurrent but Preventable Pulseless Electrical Activity Arrest: Follow the Guidelines! Circ Heart Fail. 2020 03; 13(3):e006781.
-
Morgan P, Keller R, Patel K. Evidence-Based Management of Vascular Malformations. Facial Plast Surg. 2016 Apr; 32(2):162-76.
-
Moon RE, Martina SD, Peacher DF, Potter JF, Wester TE, Cherry AD, Natoli MJ, Otteni CE, Kernagis DN, White WD, Freiberger JJ. Swimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction With Sildenafil. Circulation. 2016 Mar 08; 133(10):988-96.
-
Butts RJ, Chowdhury SM, Baker GH, Bandisode V, Savage AJ, Atz AM. Effect of Sildenafil on Pressure-Volume Loop Measures of Ventricular Function in Fontan Patients. Pediatr Cardiol. 2016 Jan; 37(1):184-91.
-
Goulopoulou S, Hannan JL, Matsumoto T, Ogbi S, Ergul A, Webb RC. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2015 Jul 15; 309(2):H297-304.
-
Leung DG, Herzka DA, Thompson WR, He B, Bibat G, Tennekoon G, Russell SD, Schuleri KH, Lardo AC, Kass DA, Thompson RE, Judge DP, Wagner KR. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol. 2014 Oct; 76(4):541-9.
-
Jackson KW, Butts RJ, Svenson AJ, McQuinn TC, Atz AM. Response to a single dose of sildenafil in single-ventricle patients: an echocardiographic evaluation. Pediatr Cardiol. 2013 Oct; 34(7):1739-42.
-
Bong GW, Rovner ES. Sexual health in adult men with spina bifida. ScientificWorldJournal. 2007 Sep 01; 7:1466-9.
-
Agrawal A, Tutuian R, Hila A, Castell DO. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci. 2005 Nov; 50(11):2059-62.